Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Recurrence 3Lymphoma, Mantle-Cell 3Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, B-Cell 2Burkitt Lymphoma 2Neoplasm, Residual 1Mature B-Cell Malignancies 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

obinutuzumab 1acalabrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × obinutuzumab × 30 days × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡